{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoproliferative+Malignancies&page=8", "query": { "condition": "Lymphoproliferative Malignancies", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 7508, "total_pages": 751, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoproliferative+Malignancies&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoproliferative+Malignancies&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T20:54:59.102Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00002682", "title": "Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Amoxicillin", "type": "DRUG" }, { "name": "Bismuth Subsalicylate", "type": "DRUG" }, { "name": "Clarithromycin", "type": "DRUG" }, { "name": "Metronidazole Hydrochloride", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Tetracycline Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 5, "start_date": "1995-08-10", "completion_date": "2001-10-08", "has_results": false, "last_update_posted_date": "2018-10-24", "last_synced_at": "2026-10-09T20:54:59.102Z", "location_count": 2, "location_summary": "Orlando, Florida • Houston, Texas", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002682" }, { "nct_id": "NCT05961696", "title": "A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory B-cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Mosunetuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2023-07-05", "completion_date": "2023-10-03", "has_results": false, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-10-09T20:54:59.102Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05961696" }, { "nct_id": "NCT00989586", "title": "Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "milatuzumab", "type": "BIOLOGICAL" }, { "name": "veltuzumab", "type": "BIOLOGICAL" }, { "name": "Correlative/Special Studies", "type": "PROCEDURE" }, { "name": "Quantitative T-, B-, and NK cell subsets", "type": "PROCEDURE" }, { "name": "Pharmacokinetics", "type": "PROCEDURE" }, { "name": "Human Anti-Human Antibodies", "type": "PROCEDURE" }, { "name": "veltuzumab and milatuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Beth Christian", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2009-09", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-02-06", "last_synced_at": "2026-10-09T20:54:59.102Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00989586" }, { "nct_id": "NCT00598169", "title": "Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "western blotting", "type": "GENETIC" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "GENETIC" ], "sponsor": "AIDS Malignancy Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 23, "start_date": "2007-11", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2020-08-10", "last_synced_at": "2026-10-09T20:54:59.102Z", "location_count": 17, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 12 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00598169" }, { "nct_id": "NCT01109069", "title": "Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-cell Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Diffuse Well-differentiated Lymphocytic Lymphoma", "B Cell Lymphoma", "Follicular Lymphoma", "Mantle Cell Lymphoma", "Non-Hodgkin's Lymphoma", "Waldenstrom Macroglobulinemia", "Burkitt Lymphoma", "B-Cell Diffuse Lymphoma" ], "interventions": [ { "name": "PCI-32765", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 199, "start_date": "2010-06", "completion_date": "2019-04-26", "has_results": true, "last_update_posted_date": "2020-05-27", "last_synced_at": "2026-10-09T20:54:59.102Z", "location_count": 16, "location_summary": "Stanford, California • Chicago, Illinois • Boston, Massachusetts + 11 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01109069" }, { "nct_id": "NCT02057445", "title": "3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkins Lymphoma", "Hodgkins Lymphoma", "Lymphoproliferative Disorder" ], "interventions": [ { "name": "EBV CTL's", "type": "DRUG" }, { "name": "Peripheral Blood Donor", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "New York Medical College", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 1, "start_date": "2014-01", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2017-12-22", "last_synced_at": "2026-10-09T20:54:59.102Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Valhalla, New York", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02057445" }, { "nct_id": "NCT02268851", "title": "A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "TGR-1202", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2014-11", "completion_date": "2022-10", "has_results": true, "last_update_posted_date": "2024-11-15", "last_synced_at": "2026-10-09T20:54:59.102Z", "location_count": 5, "location_summary": "Monterey, California • Hartford, Connecticut • Brewer, Maine + 1 more", "locations": [ { "city": "Monterey", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Brewer", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02268851" }, { "nct_id": "NCT04138875", "title": "A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "PTLD", "Lymphoid Tumor", "Hematopoietic/Lymphoid Cancer", "Plasmacytic Hyperplasia PTLD", "Infectious Mononucleosis", "Florid Follicular Hyperplasia PTLD", "Polymorphic PTLD", "Monomorphic PTLD", "Classical Hodgkin Lymphoma Type PTLD" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2022-01", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2022-06-23", "last_synced_at": "2026-10-09T20:54:59.102Z", "location_count": 2, "location_summary": "New Haven, Connecticut • Rochester, Minnesota", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04138875" }, { "nct_id": "NCT03297424", "title": "A Study of PLX2853 in Advanced Malignancies.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Cancer", "Uveal Melanoma", "Ovarian Clear Cell Carcinoma", "Non-Hodgkin Lymphoma", "Advanced Malignancies", "Solid Tumor", "Diffuse Large B Cell Lymphoma", "Follicular Lymphoma" ], "interventions": [ { "name": "PLX2853", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Opna Bio LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2017-09-12", "completion_date": "2021-06-07", "has_results": false, "last_update_posted_date": "2022-07-25", "last_synced_at": "2026-10-09T20:54:59.102Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Miami, Florida • New York, New York + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03297424" }, { "nct_id": "NCT01701323", "title": "Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Leukemia of Ambiguous Lineage", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion", "type": "BIOLOGICAL" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Nohla Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "30 Years", "sex": "ALL", "summary": "6 Months to 30 Years" }, "enrollment_count": 7, "start_date": "2012-12-10", "completion_date": "2018-05-10", "has_results": false, "last_update_posted_date": "2019-03-01", "last_synced_at": "2026-10-09T20:54:59.102Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Seattle, Washington", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01701323" } ] }